<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4296">
  <stage>Registered</stage>
  <submitdate>18/11/2013</submitdate>
  <approvaldate>18/11/2013</approvaldate>
  <nctid>NCT01991184</nctid>
  <trial_identification>
    <studytitle>A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.</studytitle>
    <scientifictitle>AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GO29089</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GDC-0853

Experimental: Dose-escalation - 


Treatment: drugs: GDC-0853
Multiple escalating doses

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety: Incidence of dose-limiting toxicities (DLTs) of GDC-0853</outcome>
      <timepoint>Approximately 1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety: Maximum tolerated dose (MTD) of GDC-0853</outcome>
      <timepoint>Approximately 1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Area under the concentration-time curve (AUC) of GDC-0853</outcome>
      <timepoint>35 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Maximum concentration (Cmax) of GDC-0853</outcome>
      <timepoint>35 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response to GDC-0853</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>Approximately 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age &gt;/= 18 years

          -  ECOG score of 0-1

          -  One of the following histologically-documented hematologic malignancies for which no
             effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular
             lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or
             chronic lymphocytic leukemia (CLL)

          -  At least one site of disease that, as seen on CT scan, is &gt; 1.5 cm in the greatest
             transverse diameter or &gt; 1.0 cm in short axis diameter (except for patients with CLL)

          -  An available tumor specimen

          -  Adequate hematologic and organ function

          -  For female patients of childbearing potential and male patients with partners of
             childbearing potential, use of effective contraceptive(s) as defined by protocol for
             the duration of the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Life expectancy &lt; 12 weeks

          -  &lt; 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic,
             experimental, hormonal or radiotherapy (with the exception of leuprolide or similar
             medications for prostate cancer)

          -  Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds

          -  Active infection requiring IV antibiotics

          -  Clinically significant history of liver disease, including viral or other hepatitis,
             current alcohol abuse, or cirrhosis.

          -  Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring
             anticonvulsants or corticosteroids for symptomatic control)

          -  History of other malignancy within 5 years prior to screening, except for
             appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, Stage
             I uterine cancer, or other cancers with a similar outcome

          -  Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for
             ventricular dysrhythmias

          -  Pregnancy, or lactation

          -  Any other diseases that contraindicates the use of an investigational drug or that may
             affect the interpretation of the results or render the patient at high risk from
             treatment complications</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>16/12/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>24</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>29/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC,WA</recruitmentstate>
    <hospital>Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology - Woolloongabba</hospital>
    <hospital>Peter MacCallum Cancer Centre; Department of Haematology - Melbourne</hospital>
    <hospital>Linear Clinical Research Limited - Nedlands</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3002 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Genentech, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label, Phase I study will evaluate the safety, tolerability, and pharmacokinetics
      of increasing doses of GDC-0853 in patients with relapsed or refractory B-cell non-Hodgkin's
      lymphoma or chronic lymphocytic leukemia. In a dose-expansion part, GDC-0853 will be assessed
      in subsets of patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01991184</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Genentech, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>